CHMP Recommends EU Approval for Brivaracetam CHMP Recommends EU Approval for Brivaracetam

The Committee for Medicinal Products for Human Use recommends marketing approval for brivaracetam (Briviact, UCB Pharma SA) as adjunctive therapy for partial-onset seizures. International Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news